糖化物作为性结肠炎的潜在药物成分:一篇评论
Yating Niu1, Jun Zhang2, Dianhua Shi2
1School of Basic Medical Science, Ningxia Medical University, Yinchuan 750004, China.
Molecules (Basel, Switzerland)
|July 14, 2023
概括
糖化物在治疗性结肠炎 (UC) 中表现有前途,通过减少炎症和氧化应激. 对这些天然化合物的进一步研究可能会导致更安全,更有效的UC疗法.
科学领域:
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
- 自然产品化学 自然产品化学
背景情况:
- 性结肠炎 (UC) 是一种不清楚病因的慢性炎症性肠病,其特征是腹痛,腹和血.
- 目前的治疗方法,如氨基酸盐,葡萄糖皮质类药物和免疫抑制剂都有局限性,包括副作用和复发,突出显示了对新疗法的需求.
- 药用植物为药物开发提供了多样化的天然化合物来源,而糖化物则成为潜在的治疗剂.
研究的目的:
- 审查性结肠炎 (UC) 的流行病学和当前治疗方法.
- 探索糖化物在治疗UC中的保护和治疗潜力.
- 阐明糖酸在UC治疗中的作用机制,指导临床前研究.
主要方法:
- 关于UC流行病学和现有药物治疗的文献综述.
- 分析关于糖化物在UC中的作用的科学证据.
- 在UC中基因糖化物作用的建议机制的审查.
主要成果:
- 糖化物通过调节炎症和免疫反应来减轻UC的潜力.
- 有证据表明,糖化物可以抑制氧化应激,这是UC病变发生的关键因素.
- 糖化物可能调节参与UC发育的信号传导通路.
结论:
- 糖化物代表了一类有前途的天然化合物,用于开发新的UC治疗方法.
- 草甘的抗炎,抗氧化和免疫调节作用为其在UC的治疗应用提供了坚实的基础.
- 需要进一步的临床前研究来验证糖化物在UC预防和治疗中的有效性和安全性.
相关概念视频
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
Inflammatory Bowel Disease II: Ulcerative Colitis
Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...


